These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 36165733)
61. [Opioid overdose prevention and naloxone diffusion (POP program): Results of an overview conducted among addiction specialized centres]. Mezaache S; Turlure F; Fredon N; Le Brun Gadelius M; Micallef J; Frauger E Therapie; 2023; 78(6):605-614. PubMed ID: 37012152 [TBL] [Abstract][Full Text] [Related]
62. Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study. Campbell G; Mattick R; Bruno R; Larance B; Nielsen S; Cohen M; Lintzeris N; Shand F; Hall WD; Hoban B; Kehler C; Farrell M; Degenhardt L BMC Pharmacol Toxicol; 2014 Mar; 15():17. PubMed ID: 24646721 [TBL] [Abstract][Full Text] [Related]
63. What is known about community pharmacy supply of naloxone? A scoping review. Nielsen S; Van Hout MC Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189 [TBL] [Abstract][Full Text] [Related]
64. Integration of Pharmacy Student Interns into a Naloxone Telephone Outreach Service. Rothbauer K; Genisot A; Frey T; JohnsonPharmacy William S Middleton Memorial Veterans Hospital D J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):208-215. PubMed ID: 35997489 [TBL] [Abstract][Full Text] [Related]
65. Pilot implementation of the PharmNet naloxone program in an independent pharmacy. Eldridge LA; Meyerson BE; Agley J J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035 [TBL] [Abstract][Full Text] [Related]
66. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Zaller ND; Yokell MA; Green TC; Gaggin J; Case P Subst Use Misuse; 2013 Jun; 48(8):590-9. PubMed ID: 23750660 [TBL] [Abstract][Full Text] [Related]
67. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis. Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025 [TBL] [Abstract][Full Text] [Related]
68. Community pharmacists' attitudes toward and practice of pharmacy-based harm reduction services in Pittsburgh, PA: a descriptive survey. O'Brien C; Klipp S; Jawa R; Wilson JD Harm Reduct J; 2024 Jul; 21(1):137. PubMed ID: 39030563 [TBL] [Abstract][Full Text] [Related]
69. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama. Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165 [TBL] [Abstract][Full Text] [Related]
70. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments. Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268 [TBL] [Abstract][Full Text] [Related]
71. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies. Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134 [TBL] [Abstract][Full Text] [Related]
72. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950 [TBL] [Abstract][Full Text] [Related]
73. State laws that authorize pharmacists to prescribe naloxone are associated with increased naloxone dispensing in retail pharmacies. Xu J; Mukherjee S Drug Alcohol Depend; 2021 Oct; 227():109012. PubMed ID: 34482035 [TBL] [Abstract][Full Text] [Related]
74. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention. Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959 [TBL] [Abstract][Full Text] [Related]
75. Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision. Barry T; Klimas J; Tobin H; Egan M; Bury G Br J Gen Pract; 2017 Apr; 67(657):e267-e273. PubMed ID: 28246098 [TBL] [Abstract][Full Text] [Related]
76. Associations between naloxone prescribing and opioid overdose among patients with acute and chronic pain conditions. Qeadan F; Madden EF Addiction; 2022 Feb; 117(2):457-471. PubMed ID: 34286895 [TBL] [Abstract][Full Text] [Related]
77. Public health detailing to increase naloxone access in NYC pharmacies. Foster CL; Tuazon E; Winkelstein E; Kunins HV; Kattan JA J Am Pharm Assoc (2003); 2023; 63(3):885-892. PubMed ID: 36997471 [TBL] [Abstract][Full Text] [Related]
78. Association of Opioid Overdose Risk Factors and Naloxone Prescribing in US Adults. Lin LA; Brummett CM; Waljee JF; Englesbe MJ; Gunaseelan V; Bohnert ASB J Gen Intern Med; 2020 Feb; 35(2):420-427. PubMed ID: 31820218 [TBL] [Abstract][Full Text] [Related]
79. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825 [TBL] [Abstract][Full Text] [Related]
80. An exploratory study of a hands-on naloxone training for rural clinicians and staff. Cody SL; Hines CB; Glenn CJ; Sharp-Marbury R; Newman S J Nurs Scholarsh; 2023 May; 55(3):599-604. PubMed ID: 36411494 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]